IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 24.96

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.62 (-1.03%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.75 (-1.01%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.83 (-0.73%)

USD 1.26B
XHE SPDR® S&P Health Care Equipme..

-0.33 (-0.37%)

USD 0.22B
SBIO ALPS Medical Breakthroughs ETF

-0.06 (-0.16%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.54 (-0.55%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.01 (-0.02%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.30 (+0.47%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.21 (-0.73%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

-0.78 (-1.34%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.47% 29% F 57% F
Dividend Return 0.48% 53% F 9% A-
Total Return 8.96% 33% F 50% F
Trailing 12 Months  
Capital Gain 14.92% 29% F 59% D-
Dividend Return 1.29% 78% C+ 17% F
Total Return 16.21% 38% F 53% F
Trailing 5 Years  
Capital Gain -4.42% 5% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.42% 5% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -1.38% 5% F 30% F
Dividend Return -0.91% 10% F 20% F
Total Return 0.48% 53% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 36.44% 5% F 27% F
Risk Adjusted Return -2.49% 14% F 24% F
Market Capitalization 0.14B 60% D- 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.